Catalent (CTLT) Stock Price & AI Analysis

NYSE
USA

$61.84

-$0.47
(-0.38%)

Subscribe to get
AI Score

Catalent Company Profile

Catalent, Inc. is a holding company, which engages in the provision of delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products. It operates through the following segments: Softgel and Oral Technologies, Biologics, Oral and Specialty Delivery, and Clinical Supply Services. The Softgel and Oral Technologies segment offers formulation, development, and manufacturing services for soft capsules or softgels, as well as large-scale production of oral solid dose forms for pharmaceutical and consumer health markets and supporting ancillary services. The Biologics segment develops and produces biologic cell-line, cell therapy, and viral vector gene therapy, formulation for parenteral dose forms, which include prefilled syringes, vials, and cartridges, and analytical development and testing services for large molecules. The Oral and Specialty Delivery segment is composed of advanced formulation of a range of technologies along with integrated downstream clinical development and commercial supply solutions. The Clinical Supply Services segment is involved in packaging, storage, distribution, and inventory management of drugs and biologics in clinical trials. The company was founded in 1933 and is headquartered in Somerset, NJ.
Catalent, Inc. is a holding company, which engages in the provision of delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products. It operates through the following segments: Softgel and Oral Technologies, Biologics, Oral and Specialty Delivery, and Clinical Supply Services. The Softgel and Oral Technologies segment offers formulation, development, and manufacturing services for soft capsules or softgels, as well as large-scale production of oral solid dose forms for pharmaceutical and consumer health markets and supporting ancillary services. The Biologics segment develops and produces biologic cell-line, cell therapy, and viral vector gene therapy, formulation for parenteral dose forms, which include prefilled syringes, vials, and cartridges, and analytical development and testing services for large molecules. The Oral and Specialty Delivery segment is composed of advanced formulation of a range of technologies along with integrated downstream clinical development and commercial supply solutions. The Clinical Supply Services segment is involved in packaging, storage, distribution, and inventory management of drugs and biologics in clinical trials. The company was founded in 1933 and is headquartered in Somerset, NJ.

Catalent | Latest news

Why Is Catalent (CTLT) Up 3.2% Since Last Earnings Report?

A month has gone by since the last earnings report for Catalent (CTLT). Shares have added about 3.2%...

Zacks - 13 hours ago

Catalent Inc (CTLT) Stock: A Value Analysis – News Heater

The public float for CTLT is 179.82M and currently, short sellers hold a 5.04% of that float. On December 04, 2024, CTLT’s average trading volume was 1.75M shares. 3 Tiny Stocks Primed to Explode ...

NewsHeater - 2 days ago

Catalent, Inc. (NYSE:CTLT) Receives $63.40 Average Target Price from Brokerages

Catalent, Inc. (NYSE:CTLT – Get Free Report) has been assigned an average rating of “Hold” from the seven research firms that are covering the stock, Marketbeat Ratings reports. Seven research ...

ETF DAILY NEWS - 1 day ago

Eli Lilly to invest $3B in Wisconsin plant expansion By Investing.com

On Thursday, Eli Lilly (NYSE:LLY) announced a substantial $3 billion investment to expand its recently acquired manufacturing facility in Pleasant Prairie, Wisconsin. The expansion aims to increase ...

Investingcom - 8 hours ago

Top Analyst Reports for Home Depot, Johnson & Johnson & Salesforce

Today's Research Daily features new research reports on 16 major stocks, including The Home Depot,...

Zacks - 7 hours ago

Lilly invests $3 billion to expand Wisconsin plant as obesity drug demand soars

, opens new tab said on Thursday it will invest $3 billion to expand the manufacturing plant it...

Reuters - 8 hours ago

How This Age-Old Battle That Could Further Rattle Eli Lilly Stock

An age-old battle in pharmaceuticals could further rattle Eli Lilly (LLY) stock and its potential...

Investor39s Business Daily - 16 hours ago

European Pharma Giants Face Challenges Amid U.S. Policy Shifts

European pharmaceutical companies, including Novo Nordisk (NVO), Roche, Novartis (NVS), AstraZeneca (AZN), GlaxoSmithKline (GSK), and Sanofi (SNY), are grapplin

Guru Focus - 7 days ago